The study combined large-scale protein post-translational modification datasets with protein-protein interaction data to profile cell signaling in lung cancer.
In December, the organization committed $1.2 million to support the creation of an ME/CFS research center at Stanford University.
Researchers have found genomic, transcriptomic, proteomic, and phenotypic variation in a comparison of HeLa cells across laboratories and over time.
The approach combines in vitro screening using phage and yeast display with screening of antibodies in tumor-bearing mice to assess their activity in vivo.
The study identified one genetic and three protein-based biomarkers associated with outcome in Pseudomonas bloodstream infections.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
Working independently, two research teams have combined CRISPR-based targeting and APEX labeling to identify proteins linked to specific portions of the genome.
The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.
Developed in the lab of Max Planck's Matthias Mann, the approach adjusts the sampling of ions during the initial scan to boost assay sensitivity and reproducibility.
The company reported total revenues of $431.7 million for the three months ended March 31, beating analysts' consensus estimate of $417.4 million.
A 30 percent decrease in instrument revenue was tempered by a 23 percent uptick in consumables revenue.
Named shieldin, the complex is involved in DNA damage repair processes and also plays a role in sensitizing BRCA1-depleted tumor cells to PARP inhibitors.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.
Researchers used a screen of mutation hotspots present in kinase active domains to identify protein kinases commonly inactivated by cancer-linked mutations.
The study used analysis of intact proteins to identify mutation-linked post-translational modifications involved in KRAS activation and membrane attachment.
While mass spec-based single-cell proteomics is still in its infancy, recently developed methods allow the ID of thousands of proteins at the single-cell level.
In a poster at this week's AACR annual meeting, researchers used the firm's tech to investigate how the addition of a cytokine agonist can improve CAR-T treatment.
With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space.
In a recent study, the researchers used the approach to profile EV-bound glycoproteins in breast cancer patients, identifying a set of potential biomarkers.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.